Patents by Inventor Fernando Jose Rebelo Do Couto
Fernando Jose Rebelo Do Couto has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20180031566Abstract: Antibodies, compositions, systems, and methods for detecting C4.4a, for example immunohistochemistry methods for detecting C4.4a using a C4.4a antibody. The antibody may be obtained by immunizing a host with a C4.4a protein such as a peptide downstream of the signal peptide. The antibodies may be adapted to detect the uPAR-like domain 1 and uPAR-like domain 2. Also featured are methods for diagnosing C4.4a-associated tumors using C4.4a antibodies disclosed herein.Type: ApplicationFiled: October 12, 2017Publication date: February 1, 2018Inventors: Fernando Jose Rebelo do Couto, Zhiming Liao, Yifei Zhu
-
Publication number: 20180009875Abstract: A method for cloning a full length coding sequence for a light chain of a rabbit monoclonal antibody is provided. In some embodiments, this method may involve: fusing a B cell from a rabbit having a B4 allotype with a 240E cell or a derivative thereof to produce a hybridoma, wherein the B cell and the hybridoma produce a monoclonal antibody; making cDNA from the hybridoma; amplifying from the cDNA a full length coding sequence for the light chain of a monoclonal antibody produced by the hybridoma using: a forward primer that hybridizes to a site in SEQ ID NO: 10, and a reverse primer having a 3? end of sequence CTARCAGTCX (SEQ ID NO: 11), wherein R is A or G and X is A, AC, ACC or ACCC; and cloning the amplified sequence into an expression vector to produce a first plasmid.Type: ApplicationFiled: December 10, 2015Publication date: January 11, 2018Inventor: Fernando Jose Rebelo Do Couto
-
Publication number: 20170146535Abstract: The invention provides antibodies that bind specifically to human indoleamine 2,3-dioxygenase 1 (IDO1), and methods of using the same. The antibodies are capable of binding to a sequence comprising SEQ ID NO: 1 and specifically bind to human IDO1 in formalin fixed paraffin embedded tissues. The antibodies are useful in a number of different analytical techniques, including immunohistochemistry (IHC) and immunocytochemistry (ICC).Type: ApplicationFiled: November 29, 2016Publication date: May 25, 2017Inventors: Fernando Jose Rebelo do Couto, Zhiming Liao, Yifei Zhu
-
Publication number: 20170073416Abstract: Provided herein are B7-H3 antibodies, fragments of such antibodies, and compositions comprising the same. The antibodies, antibody fragments and compositions are useful in a number of analytical methods, including immunohistochemical and immunocytochemical detection and analysis of B7-H3. Also provided herein are isolated peptides, compositions, and fusion proteins containing immunogenic determinants for said B7-H3 antibodies, animals immunized with the peptides and fusion proteins, isolated B cells obtained from the animals, and hybridomas made from the isolated B cells.Type: ApplicationFiled: November 29, 2016Publication date: March 16, 2017Inventors: Fernando Jose Rebelo do Couto, Zhiming Liao, Yifei Zhu
-
Publication number: 20150346208Abstract: Provided herein are novel PD-L1 antibodies and methods for using the same for diagnosing a medical condition associated with elevated PD-L1 levels (e.g., cancer) in subjects in need thereof and antigen binding fragments thereof. The PD-L1 antibodies and antigen binding fragments are also useful in evaluating the efficacy of a particular therapeutic regime in a subject diagnosed as having a PD-L1-related medical condition.Type: ApplicationFiled: May 29, 2015Publication date: December 3, 2015Inventors: Fernando Jose Rebelo do Couto, Zhiming Liao, Yifei Zhu
-
Publication number: 20150038370Abstract: The invention provides a method for identifying positions of an antibody that can be modified without significantly reducing the binding activity of the antibody. In many embodiments, the method involves identifying a substitutable position in a parent antibody by comparing its amino acid sequence to the amino acid sequences of a number of related antibodies that each bind to the same antigen as the parent antibody. The amino acid at the substitutable position may be substituted for a different amino acid without significantly affecting the activity of the antibody. The subject methods may be employed to change the amino acid sequence of a CDR without significantly reducing the affinity of the antibody of the antibody, in humanization methods, or in other antibody engineering methods. The invention finds use in a variety of therapeutic, diagnostic and research applications.Type: ApplicationFiled: October 20, 2014Publication date: February 5, 2015Inventors: Fernando Jose Rebelo Do Couto, KRISTIN BETH HENDRICKS, STACEY ELLEN WALLACE, GUO-LIANG YU
-
Patent number: 8444984Abstract: The invention provides monoclonal antibodies that neutralize TNF? activity. The monoclonal antibodies may be rabbit monoclonal antibodies or monoclonal antibodies having CDR regions derived from those rabbit monoclonal antibodies. In certain embodiments, the monoclonal antibodies may be humanized. Methods of using the subject antibodies to inhibit TNF? activity, methods of treatment using those antibodies and kits containing the same are also provided. The invention finds use in a variety of research and medical applications.Type: GrantFiled: June 7, 2012Date of Patent: May 21, 2013Assignee: Epitomics, Inc.Inventors: Fernando Jose Rebelo Do Couto, Kristin Beth Hendricks, Stacey Ellen Wallace
-
Patent number: 8404816Abstract: The invention provides a method for identifying positions of an antibody that can be modified without significantly reducing the binding activity of the antibody. In many embodiments, the method involves identifying a substitutable position in a parent antibody by comparing its amino acid sequence to the amino acid sequences of a number of related antibodies that each bind to the same antigen as the parent antibody. The amino acid at the substitutable position may be substituted for a different amino acid without significantly affecting the activity of the antibody. The subject methods may be employed to change the amino acid sequence of a CDR without significantly reducing the affinity of the antibody of the antibody, in humanization methods, or in other antibody engineering methods. The invention finds use in a variety of therapeutic, diagnostic and research applications.Type: GrantFiled: May 3, 2011Date of Patent: March 26, 2013Assignee: Epitomics, Inc.Inventors: Fernando Jose Rebelo Do Couto, Kristin B. Hendricks, S. Ellen Wallace, Guo-Liang Yu
-
Publication number: 20120329069Abstract: The invention provides a method for identifying positions of an antibody that can be modified without significantly reducing the binding activity of the antibody. In many embodiments, the method involves identifying a substitutable position in a parent antibody by comparing its amino acid sequence to the amino acid sequences of a number of related antibodies that each bind to the same antigen as the parent antibody. The amino acid at the substitutable position may be substituted for a different amino acid without significantly affecting the activity of the antibody. The subject methods may be employed to change the amino acid sequence of a CDR without significantly reducing the affinity of the antibody of the antibody, in humanization methods, or in other antibody engineering methods. The invention finds use in a variety of therapeutic, diagnostic and research applications.Type: ApplicationFiled: August 10, 2012Publication date: December 27, 2012Inventors: Fernando Jose Rebelo Do Couto, Kristin B. Hendricks, S. Ellen Wallace, Guo-Liang Yu
-
Publication number: 20120269809Abstract: The invention provides monoclonal antibodies that neutralize TNF? activity. The monoclonal antibodies may be rabbit monoclonal antibodies or monoclonal antibodies having CDR regions derived from those rabbit monoclonal antibodies. In certain embodiments, the monoclonal antibodies may be humanized. Methods of using the subject antibodies to inhibit TNF? activity, methods of treatment using those antibodies and kits containing the same are also provided. The invention finds use in a variety of research and medical applications.Type: ApplicationFiled: June 7, 2012Publication date: October 25, 2012Inventors: FERNANDO JOSE REBELO DO COUTO, Kristin Beth Hendricks, Stacey Ellen Wallace
-
Patent number: 8211433Abstract: The invention provides monoclonal antibodies that neutralize TNF? activity. The monoclonal antibodies may be rabbit monoclonal antibodies or monoclonal antibodies having CDR regions derived from those rabbit monoclonal antibodies. In certain embodiments, the monoclonal antibodies may be humanized. Methods of using the subject antibodies to inhibit TNF? activity, methods of treatment using those antibodies and kits containing the same are also provided. The invention finds use in a variety of research and medical applications.Type: GrantFiled: April 29, 2011Date of Patent: July 3, 2012Assignee: Epitomics, Inc.Inventors: Fernando Jose Rebelo Do Couto, Kristin Beth Hendricks, Stacey Ellen Wallace
-
Publication number: 20120003671Abstract: The invention provides a method for identifying positions of an antibody that can be modified without significantly reducing the binding activity of the antibody. In many embodiments, the method involves identifying a substitutable position in a parent antibody by comparing its amino acid sequence to the amino acid sequences of a number of related antibodies that each bind to the same antigen as the parent antibody. The amino acid at the substitutable position may be substituted for a different amino acid without significantly affecting the activity of the antibody. The subject methods may be employed to change the amino acid sequence of a CDR without significantly reducing the affinity of the antibody of the antibody, in humanization methods, or in other antibody engineering methods. The invention finds use in a variety of therapeutic, diagnostic and research applications.Type: ApplicationFiled: May 3, 2011Publication date: January 5, 2012Inventors: Fernando Jose Rebelo Do Couto, Kristin B. Hendricks, S. Ellen Wallace, Guo-Liang Yu
-
Publication number: 20110243936Abstract: The invention provides monoclonal antibodies that neutralize TNF? activity. The monoclonal antibodies may be rabbit monoclonal antibodies or monoclonal antibodies having CDR regions derived from those rabbit monoclonal antibodies. In certain embodiments, the monoclonal antibodies may be humanized. Methods of using the subject antibodies to inhibit TNF? activity, methods of treatment using those antibodies and kits containing the same are also provided. The invention finds use in a variety of research and medical applications.Type: ApplicationFiled: April 29, 2011Publication date: October 6, 2011Inventors: FERNANDO JOSE REBELO DO COUTO, KRISTIN BETH HENDRICKS, STACEY ELLEN WALLACE
-
Patent number: 7960517Abstract: The invention provides a method for identifying positions of an antibody that can be modified without significantly reducing the binding activity of the antibody. In many embodiments, the method involves identifying a substitutable position in a parent antibody by comparing its amino acid sequence to the amino acid sequences of a number of related antibodies that each bind to the same antigen as the parent antibody. The amino acid at the substitutable position may be substituted for a different amino acid without significantly affecting the activity of the antibody. The subject methods may be employed to change the amino acid sequence of a CDR without significantly reducing the affinity of the antibody of the antibody, in humanization methods, or in other antibody engineering methods. The invention finds use in a variety of therapeutic, diagnostic and research applications.Type: GrantFiled: October 31, 2008Date of Patent: June 14, 2011Assignee: Epotimics, Inc.Inventors: Fernando Jose Rebelo Do Couto, Kristin B. Hendricks, S. Ellen Wallace, Guo-Liang Yu
-
Patent number: 7959921Abstract: The invention provides monoclonal antibodies that neutralize TNF? activity. The monoclonal antibodies may be rabbit monoclonal antibodies or monoclonal antibodies having CDR regions derived from those rabbit monoclonal antibodies. In certain embodiments, the monoclonal antibodies may be humanized. Methods of using the subject antibodies to inhibit TNF? activity, methods of treatment using those antibodies and kits containing the same are also provided. The invention finds use in a variety of research and medical applications.Type: GrantFiled: August 21, 2008Date of Patent: June 14, 2011Assignee: Epitomics, Inc.Inventors: Fernando Jose Rebelo Do Couto, Kristin Beth Hendricks, Stacey Ellen Wallace
-
Publication number: 20090202558Abstract: The invention provides monoclonal antibodies that neutralize TNF? activity. The monoclonal antibodies may be rabbit monoclonal antibodies or monoclonal antibodies having CDR regions derived from those rabbit monoclonal antibodies. In certain embodiments, the monoclonal antibodies may be humanized. Methods of using the subject antibodies to inhibit TNF? activity, methods of treatment using those antibodies and kits containing the same are also provided. The invention finds use in a variety of research and medical applications.Type: ApplicationFiled: August 21, 2008Publication date: August 13, 2009Inventors: FERNANDO JOSE REBELO DO COUTO, Kristin Beth Hendricks, Stacey Ellen Wallace
-
Publication number: 20090155824Abstract: The invention provides a method for identifying positions of an antibody that can be modified without significantly reducing the binding activity of the antibody. In many embodiments, the method involves identifying a substitutable position in a parent antibody by comparing its amino acid sequence to the amino acid sequences of a number of related antibodies that each bind to the same antigen as the parent antibody. The amino acid at the substitutable position may be substituted for a different amino acid without significantly affecting the activity of the antibody. The subject methods may be employed to change the amino acid sequence of a CDR without significantly reducing the affinity of the antibody of the antibody, in humanization methods, or in other antibody engineering methods. The invention finds use in a variety of therapeutic, diagnostic and research applications.Type: ApplicationFiled: October 31, 2008Publication date: June 18, 2009Inventors: FERNANDO JOSE REBELO DO COUTO, Kristin B. Hendricks, S. Ellen Wallace, Guo-Liang Yu
-
Patent number: 7462697Abstract: The invention provides a method for identifying positions of an antibody that can be modified without significantly reducing the binding activity of the antibody. In many embodiments, the method involves identifying a substitutable position in a parent antibody by comparing its amino acid sequence to the amino acid sequences of a number of related antibodies that each bind to the same antigen as the parent antibody. The amino acid at the substitutable position may be substituted for a different amino acid without significantly affecting the activity of the antibody. The subject methods may be employed to change the amino acid sequence of a CDR without significantly reducing the affinity of the antibody of the antibody, in humanization methods, or in other antibody engineering methods. The invention finds use in a variety of therapeutic, diagnostic and research applications.Type: GrantFiled: November 8, 2004Date of Patent: December 9, 2008Assignee: Epitomics, Inc.Inventors: Fernando Jose Rebelo Do Couto, Kristin B. Hendricks, S. Ellen Wallace, Guo-Liang Yu
-
Patent number: 7431927Abstract: The invention provides monoclonal antibodies that neutralize TNF? activity. The monoclonal antibodies may be rabbit monoclonal antibodies or monoclonal antibodies having CDR regions derived from those rabbit monoclonal antibodies. In certain embodiments, the monoclonal antibodies may be humanized. Methods of using the subject antibodies to inhibit TNF? activity, methods of treatment using those antibodies and kits containing the same are also provided. The invention finds use in a variety of research and medical applications.Type: GrantFiled: March 24, 2005Date of Patent: October 7, 2008Assignee: Epitomics, Inc.Inventors: Fernando Jose Rebelo Do Couto, Kristin Beth Hendricks, Stacey Ellen Wallace
-
Publication number: 20040086979Abstract: The invention provides methods for producing a modified nucleic acid that encodes a modified a rabbit antibody so that the modified rabbit antibody is less immunogenic in a non-rabbit host than an unmodified parent rabbit antibody. The invention further provides modified nucleic acids made by these methods, as well as vectors and host cells comprising the nucleic acids, and methods for producing the encoded modified antibodies. Also provided are modified rabbit antibodies encoded by subject nucleic acids, and compositions containing the same. The invention further provides kits for carrying out the subject methods.Type: ApplicationFiled: August 7, 2003Publication date: May 6, 2004Inventors: Dongxiao Zhang, Guoliang Yu, Robert Pytela, Fernando Jose Rebelo Do Couto